Table 1.
Participant characteristics
| Total sample (N = 175) | ApoE4+ (N = 40) | ApoE4− (N = 135) | Florbetapir+ (N = 50) | Florbetapir− (N = 125) | |
|---|---|---|---|---|---|
| Age | 77.2 (6.0) | 76.8 (5.6) | 77.3 (6.1) | 78.3 (4.8) | 76.7 (6.4) |
| Sex (M/F) | 87/88 | 20/20 | 67/68 | 22/28 | 65/60 |
| Education | 16.3 (2.8) | 15.9 (2.9) | 16.5 (2.7) | 16 (3) | 16.5 (2.7) |
| MMSEa | 29 (1.2) | 28.6 (1.3) | 29.1 (1.2) | 29 (1.2) | 29 (1.2) |
| ADAS-Cogb | 6 (3.1) | 6.8 (3.6) | 5.9 (2.9) | 6.4 (3.3) | 6 (3) |
| ApoE2 carriersc | 23 | 1 | 22 | 4 | 19 |
aApoE4− has significantly higher MMSE than ApoE4+ (t = 2.35, p = 0.02).
bAlzheimer's Disease Assessment Scale–cognitive subscale.
cApoE2 is more common with ApoE4− than ApoE4+ (χ2 = 5.1, p = 0.02).